| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in INDV over the last quarter tilts toward buying: insiders added a net 3,000 shares worth roughly $108K.
Classified under Pharmaceuticals (Health Care sector), INDV's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 790.3K | $30.29M | - | |
| CFO | 284.8K | $10.74M | - | |
| Other | 209.3K | $8.61M | - | |
| Other | 71.5K | - | - | |
| Other | 31.4K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Stejbach Mark | Director | Buy10b5-1 | 775 | $35.39 | $27,429.27 | +4.8% | -16.1% | - | |
| Jan 5, 2026 | Wheadon David E. | Director | Buy10b5-1 | 1,771 | $35.39 | $62,680.29 | +14.0% | -16.1% | - | |
| Jan 5, 2026 | Ninivaggi Daniel A | Director | Buy10b5-1 | 775 | $35.39 | $27,429.27 | +4.8% | -16.1% | - |